MEISSA VACCINES INC
Live attenuated RSV vaccine for infants
- Sector
- Biotech
- Headquarters
- SOUTH SAN FRANCISCO, CA
- Founded
- 2014
- Latest Form D
- $13.9M, Oct 2019
- Total capital
- $18.3M
- Federal grants
- $3.1M
- 5 awards · 2017–2019
- Rank in peer group#224 of 326
- Private capital raised
- $15.2M
- 2 Form D · last Oct 2019
- 85 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 0
- 10 pending
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 2nd filing$13.9M
- Federal grantHealth and Human S · Phase II · Development of live attenuated respiratory syncytial virus vaccines with novel thermal stable fusion protein$340K
- Federal grantHealth and Human S · Phase II · Development of live attenuated respiratory syncytial virus vaccines with novel thermal stable fusion protein$1.3M
- Federal grantHealth and Human S · Phase II · Development of live attenuated respiratory syncytial virus vaccines with novel thermal stable fusion protein$1.0M
- Private capital raisedForm D · SEC · 1st filing$1.2M
- Federal grantHealth and Human S · Phase II · Development of live attenuated respiratory syncytial virus vaccines with novel thermal stable fusion protein$224K
- Federal grantHealth and Human S · Phase I · Development of polyvalent inactivated rhinovirus vaccine$216K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Federal first
8months
from MEISSA VACCINES INC’s first federal award to its first private round.
- First federal award · Feb 2017
- Health and Human S · $216K
- First Form D · Oct 2017
- $1.2M · 1st Form D
- Awards before first raise
- 2 awards
An association in public records, not a cause or a prediction.
Standing among 326 peers
Line = medianBiotech · Molecule
- Federal grantsBelow median
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Roderick TangResearcherExecutive OfficerLinked by $3.1M in grants as PI
- Isaac ChengDirectorNamed in SEC Form D filings
- Kenneth KelleyDirectorNamed in SEC Form D filings
- Martin MooreExecutive Officer, Director, PromoterNamed in SEC Form D filings
- Stephanie O?BrienDirectorNamed in SEC Form D filings
- William DalyDirectorNamed in SEC Form D filings
What it has protected
USPTO · 0 granted of 10- PendingRsv Vaccines And Methods Of Administering SameUSPTOApplication 18202836
- PendingChimeric Rsv And Coronavirus Proteins, Immunogenic Compositions, And Methods Of UseUSPTOApplication 18010436
- PendingMethods Of Administering Chimeric VaccinesUSPTOApplication PCTUS2022080185
Show all 10 patent records
- Rsv Vaccines And Methods Of Administering SameMar 14, 2024 · Application 18202836Pending
- Chimeric Rsv And Coronavirus Proteins, Immunogenic Compositions, And Methods Of UseAug 10, 2023 · Application 18010436Pending
- Methods Of Administering Chimeric VaccinesApplication PCTUS2022080185Pending
- Rsv Vaccines And Methods Of Administering SameApplication 63382527Pending
- Rsv Vaccines And Methods Of Administering SameApplication 63346623Pending
- Methods Of Administering Chimeric VaccinesApplication 63281403Pending
- Chimeric Rsv And Coronavirus Proteins, Immunogenic Compositions, And Methods Of UseApplication PCTUS2021037846Pending
- Chimeric Rsv And Coronavirus Proteins, Immunogenic Compositions, And Methods Of UseApplication 63194092Pending
- Chimeric Rsv And Coronavirus Proteins, Immunogenic Compositions, And Methods Of UseApplication 63160445Pending
- Chimeric Rsv And Coronavirus Proteins, Immunogenic Compositions, And Methods Of UseApplication 63040193Pending
Related companies, and why
- LifeCyte Innovations, Inc.Similar federal contract value in Biotech · null in contracts
- Revalesio CorpSimilar federal contract value in Biotech · null in contracts
- Triumvira Immunologics Inc.Similar federal contract value in Biotech · null in contracts
- DRUG DESIGN METHODOLOGIES, L.L.C.Similar federal contract value in Biotech · null in contracts
- AdvanCellSimilar federal contract value in Biotech · null in contracts
- TARN BIOSCIENCES, INC.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .